Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [177Lu]Lu-PSMA-I&T for triple-negative breast cancer

Fig. 2

A Tumor growth analysis comparing the time period (in days) until reaching 200% of the initial tumor volume (TV) in control and therapy receiving groups (n ≥ 5); ** p = 0.008). B Kaplan–Meier survival of single dose and fractionated dose group compared to the control

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us